PATH (global health organization)

Last updated
PATH
Company typeNonprofit organization
Founded1977;47 years ago (1977)
Headquarters Seattle
Key people
Nikolaj Gilbert, President and CEO
RevenueUS$303,223,000 (as of 2020) [1]
Total assets 335,091,155 United States dollar (2022)  OOjs UI icon edit-ltr-progressive.svg
Number of employees
1,600
Website www.path.org

PATH (formerly known as the Program for Appropriate Technology in Health) is an international, nonprofit global health organization. [2] PATH is based in Seattle with 1,600 employees in more than 70 countries around the world. Its president and CEO is Nikolaj Gilbert, who is also the Managing Director and CEO of Foundations for Appropriate Technologies in Health (FATH), PATH's Swiss subsidiary. PATH focuses on six platforms: vaccines, drugs, diagnostics, devices, system, and service innovations.

Contents

History

Founded in 1977 as the Program for the Introduction and Adaptation of Contraceptive Technology with a focus on family planning, PATH soon broadened its purpose to work on a wide array of emerging and persistent global health issues in the areas of health technologies, maternal health, child health, reproductive health, vaccines and immunization, and emerging and epidemic diseases such as HIV, malaria, tuberculosis, and COVID-19.

In 2000, PATH had 300 employees and an annual budget of $60 million. In 2020, this increased to 1,600 employees and a budget of $323 million. [3]

Developed technologies

Vaccine and pharmaceutical technologies

PATH collaborated with the World Health Organization starting in 1979 to develop the vaccine vial monitor, a small sticker that adheres to a vaccine vial and changes color as the vaccine is exposed to heat over time. The sticker shows when a vaccine has reached its preset temperature limit and can no longer be safely used. It took over thirty years until 2007 for the widespread adoption of this technology by vaccine manufacturers. [4] UNICEF requires these monitors on all vaccines it purchases. [5]

PATH also developed the Uniject injection system. The single-dose, autodisabling injection system consists of a needle attached to a small bubble of plastic that is prefilled with medication. The system is designed to prevent disease transmission and requires low training to administer vaccine and other drugs safely, intended for remote villages. [6]

Nutrition

Developed by Bon Dente International, Ultra Rice is a manufactured grain owned by PATH. Designed to resemble the texture and appearance of regular rice, it is a micronutrient fortified grain that can be mixed with rice to reduce malnutrition in countries where rice is a staple food. [7] The micronutrients include zinc, folic acid and iron, and it is capable of reducing the incidence of anemia and infant (6-24 month old) mortality in low-income populations. It is typically mixed with regular rice at a 1:100 ratio. Ultra Rice has been produced and tested in several countries, including Brazil, Burundi, and India, where it has been served in school-lunch programs. [8] [9] Starting in 2010, PATH distributed Ultra Rice to Cambodia through food assistance programs and for further research, for which it now has over thirty studies. The results showed that fortified rice was well accepted by children, parents and teachers and consumption of it was similar or better than normal rice. [10] In 2012, PATH entered a business partnership in Brazil with a commercial rice producer to sell Ultra Rice mixed in with regular rice at supermarkets. [11]

Sexual and reproductive health

PATH technologies address sexual and reproductive health include:

Water and sanitation

PATH looks at ways to improve water quality in developing countries, including helping companies develop low-cost filters, gadgets, and other water-treatment products to stimulate a commercial market and keep prices low. [16] Most recently, PATH partnered with Splash! to develop and test a handwashing station for use in LMICs, specifically in response to the COVID-19 pandemic.

Vaccines and immunization

Starting in 2010, PATH has collaborated with biotechnology and pharmaceutical companies to support the development of vaccines for diseases such as meningitis [17] and pneumonia and to help countries introduce vaccines for childhood illnesses such as rotavirus and Japanese encephalitis.

Meningitis

PATH and the World Health Organization, through the Meningitis Vaccine Project, led the development of a vaccine called MenAfriVac to end meningitis A epidemics in sub-Saharan Africa, where 450 million people in 26 countries are at risk of the disease. The vaccine was developed by Serum Institute of India and introduced in Burkina Faso, Mali, and Niger in December 2010 to prevent the spread of a strain of meningitis found only in Africa. Within six months, the vaccine eliminated new cases of meningitis A in the areas where it was introduced. [17] By the end of 2012, the vaccine had reached 100 million people in ten countries: Benin, Burkina Faso, Cameroon, Chad, Ghana, Mali, Niger, Nigeria, Senegal, and Sudan. [18] The introduction of MenAfriVac marked the first time that a vaccine was developed for a disease only found in Africa. [19]

Previously used meningitis vaccines had low efficacy and cost USD $80 per dose. The new vaccine has high efficacy against the type of meningitis that is most prevalent in Africa and costs less than $0.50 per dose. [20] The entire vaccination research and development project cost less than US$100 million, about one-fifth the typical cost for developing a vaccine. [21]

In 2012, MenAfriVac was also approved for storage without refrigeration for up to four days, enabling health workers to more easily reach patients in rural villages or in areas with no power. [22]

Rotavirus

PATH supports the introduction of vaccines against rotavirus in developing countries to protect young children from severe diarrhea. In 2006, PATH helped Nicaragua become the first developing country to introduce rotavirus vaccines within months of their introduction. [23] Former PATH researcher John Wecker noted that rotavirus infections dropped in areas that began to use the vaccine after the WHO recommended its international use in 2009. [24]

PATH also conducts research to show the impact of rotavirus vaccines and help countries choose whether to adopt the vaccines into their immunization programs. [25]

Japanese encephalitis

PATH works in India and other countries in the region to introduce an affordable vaccine to protect against Japanese encephalitis—a disease the World Health Organization estimates claims 10,000 to 15,000 lives a year, mostly children, and causes permanent brain damage in many more. [26] In 2006, PATH helped the government of India launch an immunization campaign for children in high-risk areas with the vaccine. [27]

Epidemic diseases

Part of PATH's work focuses on some of the most widespread and threatening global diseases: malaria, HIV/AIDS, tuberculosis, and influenza.

Malaria

The PATH Malaria Vaccine Initiative supports several malaria vaccine candidates at various stages of development around the world, including the most advanced candidate, called RTS,S. Researchers studied RTS,S, made by GlaxoSmithKline, in phase 3 clinical trials among infants and young children in sub-Saharan Africa. A 2011 study showed the vaccine provided about 50 percent protection against malaria for young children ages 5 to 17 months, and another 2012 study showed a 33 percent reduction in infants. [28] In October 2013, GlaxoSmithKline reported that the experimental vaccine reduced the number of cases amongst young children by almost 50 percent and among infants by around 25 percent, following the conclusion of an 18-month clinical trial. GlaxoSmithKline is set to submit an application for a marketing license with the European Medicines Agency (EMA) in 2014. The new vaccine has the backing of the UN's Swiss-based WHO which states that it will recommend the use of RTS,S for use starting in 2015, providing it gets approval. [29]

Another PATH initiative to address malaria is the Malaria Control and Evaluation Partnership in Africa (MACEPA), which focuses on controlling malaria through the use of insecticide-treated bednets, indoor spraying of insecticides, new diagnostic tools to find infection, and effective medicines for treatment. [30] In Zambia, this work has helped decrease the rate of malaria among children younger than age 5 by 50 percent in two years. [30]

In December 2012, PATH received an award from the US President's Malaria Initiative for a new malaria project focused on "the expansion of high-quality diagnosis and treatment for malaria and other childhood illnesses and infectious diseases." [31]

PATH's Drug Development program, which grew out of an affiliation with OneWorld Health, is advancing a new, semisynthetic form of the malaria drug artemisinin that will bolster the current, volatile botanical supply. [32] [33] In August 2014, PATH and Sanofi announced the release of the first batch of semisynthetic artemisinin. 1.7 million doses of Sanofi's ArteSunate AmodiaQuine Winthrop (ASAQ Winthrop), a fixed-dose artemisinin-based combination therapy will be shipped to half a dozen African countries over the next few months. [34]

HIV/AIDS

PATH works in Africa, Asia, and other regions to slow the spread of HIV/AIDS and provide support for people affected by the disease. For example, in Kenya, PATH has conducted over two decades of research into HIV and pregnancy prevention. [35] PATH also provides support groups and health services for married adolescents and other groups at high risk for HIV. [36] It also liases with local governments and community organizations to strengthen and expand services for HIV/AIDS, malaria, tuberculosis, and maternal and newborn health. [37]

Other PATH projects to address HIV in Africa include improving access to HIV treatment and services in Ethiopia [38] and expanding HIV counseling and testing and other services in the Democratic Republic of Congo. [39]

PATH uses behavior change communication techniques to encourage healthy behaviors for HIV prevention. One of the best-known examples is PATH's work with "magnet theater" in Kenya, India, Vietnam, and other developing countries. Named because of its natural pulling power, this interactive street theater draws people in rural communities to clearings, dirt roads, and village centers—any open space where people can gather. There, actors banter with their audiences and pull them into the play, stimulating dialogue about HIV/AIDS and other taboo subjects and helping individuals re-examine behaviors that contribute to poor health.

Maternal and child health

In addition to its work on vaccines for childhood illnesses, PATH addresses pregnancy complications, nutrition issues, and other health challenges that affect women and children in developing countries and lead to higher rates of illness and death.

In 2012, PATH completed a seven-year project in India focused on safe birth for mothers and babies. PATH worked with local governments and community groups to encourage community leaders, health workers, pregnant women, and families to deliver babies in health centers, rather than at home, and adopt other best practices to protect mothers and their infants during pregnancy, childbirth, and infancy. The project used community outreach approaches including door-to-door clinical surveillance, distribution of printed health materials, and street theater to spread messages about maternal and newborn health. [40]

In South Africa, PATH leads a five-year project to improve the health and development of 750,000 pregnant women and children by encouraging breastfeeding and improving health care for pregnant women and young children. [41]

Funding and expenses

PATH's income in 2020 was $303,223,000 and its expenses in 2020 were US$294,369,000. 86.4% of its budget was spent on program activities, 12.8% on administration, and .8% on fundraising. [3]

In 2010, PATH received the most US foundation grants in the state of Washington and ranked thirteenth among international recipients of US foundation grants. [42]

Controversies

In 2012, the NGO was warned by the Indian government after one of its studies involving an HPV vaccine resulted in the alleged death of seven girls belonging to an indigenous community (tribe) in India. [43]

All 7 deaths were later attributed to other causes, including a snake bite, drowning, suicide by pesticide ingestion, and complications from malaria. [44]

In what The Hindu called "a shockingly unethical trial", nearly 2,800 consent forms were signed by a hostel warden or headmaster, as the 'guardian'. [45]

Recognition

In 2003, PATH received the Tech Museum's Dr. Alejandro Zaffaroni Health Award for its work on the Uniject device, a sterile pre-filled, single-use syringe. [46]

Since 2005, PATH has remained on Forbes' top 200 list of the 200 largest charities in America. [47]

For five years running, Fast Company magazine in 2008 named PATH as one of the top social entrepreneurs who are changing the world. [48]

In 2009, PATH received the Conrad N. Hilton Humanitarian Prize. [49]

In 2012, PATH was ranked as the sixth best NGO in the world on the "top 100" list published by The Global Journal. [50]

As of March 2019, PATH has been vetted and is in good standing as part of GlobalGiving's GG Rewards program. [51]

See also

Related Research Articles

<span class="mw-page-title-main">Malaria</span> Mosquito-borne infectious disease

Malaria is a mosquito-borne infectious disease that affects vertebrates and Anopheles mosquitoes. Human malaria causes symptoms that typically include fever, fatigue, vomiting, and headaches. In severe cases, it can cause jaundice, seizures, coma, or death. Symptoms usually begin 10 to 15 days after being bitten by an infected Anopheles mosquito. If not properly treated, people may have recurrences of the disease months later. In those who have recently survived an infection, reinfection usually causes milder symptoms. This partial resistance disappears over months to years if the person has no continuing exposure to malaria. The mosquito vector is itself harmed by Plasmodium infections, causing reduced lifespan.

<span class="mw-page-title-main">HIV/AIDS in Africa</span>

HIV/AIDS originated in the early 20th century and has become a major public health concern and cause of death in many countries. AIDS rates vary significantly between countries, with the majority of cases concentrated in Southern Africa. Although the continent is home to about 15.2 percent of the world's population, more than two-thirds of the total population infected worldwide – approximately 35 million people – were Africans, of whom around 1 million have already died. Eastern and Southern Africa alone accounted for an estimate of 60 percent of all people living with HIV and 100 percent of all AIDS deaths in 2011. The countries of Eastern and Southern Africa are most affected, leading to raised death rates and lowered life expectancy among adults between the ages of 20 and 49 by about twenty years. Furthermore, life expectancy in many parts of Africa is declining, largely as a result of the HIV/AIDS epidemic, with life-expectancy in some countries reaching as low as thirty-nine years.

<span class="mw-page-title-main">Tropical medicine</span> Interdisciplinary branch of medicine

Tropical medicine is an interdisciplinary branch of medicine that deals with health issues that occur uniquely, are more widespread, or are more difficult to control in tropical and subtropical regions.

<span class="mw-page-title-main">Global health</span> Health of populations in a global context

Global health is the health of populations in a worldwide context; it has been defined as "the area of study, research, and practice that places a priority on improving health and achieving equity in health for all people worldwide". Problems that transcend national borders or have a global political and economic impact are often emphasized. Thus, global health is about worldwide health improvement, reduction of disparities, and protection against global threats that disregard national borders, including the most common causes of human death and years of life lost from a global perspective.

Since October 2018, the Center for Global Infectious Disease Research has been part of the Seattle Children's Research Institute. At the time of the merger, CID Research had 166 scientists. Its mission was to eliminate the world's most devastating infectious diseases through leadership in scientific discovery. The organization's research labs were in the South Lake Union area of Seattle, WA. The institute's research focused on four areas of infectious disease: HIV/AIDS, malaria, tuberculosis (TB), and Emerging & Neglected Diseases (END) like African sleeping sickness, leishmaniasis, Chagas disease, and toxoplasmosis. CID Research was engaged in early stages of the scientific pipeline including bench science and malaria clinical trials and has expertise in immunology, vaccinology, and drug discovery.

<span class="mw-page-title-main">HPV vaccine</span> Class of vaccines against human papillomavirus

Human papillomavirus (HPV) vaccines are vaccines intended to provide acquired immunity against infection by certain types of human papillomavirus (HPV). The first HPV vaccine became available in 2006. Currently there are six licensed HPV vaccines: three bivalent, two quadrivalent, and one nonavalent vaccine All have excellent safety profiles and are highly efficacious, or have met immunobridging standards. All of them protect against HPV types 16 and 18, which are together responsible for approximately 70% of cervical cancer cases globally. The quadrivalent vaccines provide additional protection against HPV types 6 and 11. The nonavalent provides additional protection against HPV types 31, 33, 45, 52 and 58. It is estimated that HPV vaccines may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer, and show more than 90% effectiveness in preventing HPV-positive oropharyngeal cancers. They also protect against penile cancer. They additionally prevent genital warts, with the quadrivalent and nonavalent vaccines providing virtually complete protection. The WHO recommends a one or two-dose schedule for girls aged 9–14 years, the same for girls and women aged 15–20 years, and two doses with a 6-month interval for women older than 21 years. The vaccines provide protection for at least five to ten years.

<span class="mw-page-title-main">Childhood immunizations in the United States</span>

The schedule for childhood immunizations in the United States is published by the Centers for Disease Control and Prevention (CDC). The vaccination schedule is broken down by age: birth to six years of age, seven to eighteen, and adults nineteen and older. Childhood immunizations are key in preventing diseases with epidemic potential.

<span class="mw-page-title-main">Meningococcal disease</span> Often life-threatening bacterial infection

Meningococcal disease describes infections caused by the bacterium Neisseria meningitidis. It has a high mortality rate if untreated but is vaccine-preventable. While best known as a cause of meningitis, it can also result in sepsis, which is an even more damaging and dangerous condition. Meningitis and meningococcemia are major causes of illness, death, and disability in both developed and under-developed countries.

<span class="mw-page-title-main">Drugs for Neglected Diseases Initiative</span> Non-profit organization

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.

Globalization, the flow of information, goods, capital, and people across political and geographic boundaries, allows infectious diseases to rapidly spread around the world, while also allowing the alleviation of factors such as hunger and poverty, which are key determinants of global health. The spread of diseases across wide geographic scales has increased through history. Early diseases that spread from Asia to Europe were bubonic plague, influenza of various types, and similar infectious diseases.

The rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. The vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of the risk of death among young children due to severe diarrhea. Immunizing babies decreases rates of disease among older people and those who have not been immunized.

<span class="mw-page-title-main">Sexually transmitted infection</span> Infection transmitted through human sexual behavior

A sexually transmitted infection (STI), also referred to as a sexually transmitted disease (STD) and the older term venereal disease (VD), is an infection that is spread by sexual activity, especially vaginal intercourse, anal sex, oral sex, or sometimes manual sex. STIs often do not initially cause symptoms, which results in a risk of transmitting them on to others. The term sexually transmitted infection is generally preferred over sexually transmitted disease or venereal disease, as it includes cases with no symptomatic disease. Symptoms and signs of STIs may include vaginal discharge, penile discharge, ulcers on or around the genitals, and pelvic pain. Some STIs can cause infertility.

<span class="mw-page-title-main">JN-International Medical Corporation</span> Pharmaceutical company in Nebraska, United States

JN-International Medical Corporation (JNIMC) is a U.S.-based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries. This private corporation was founded in 1998 by Dr. Jeeri R. Reddy with the help of Dr. Kelly F. Lechtenberg in a small rural town, Oakland, Nebraska. From there it grew and expanded until in the year 2000 the corporation moved to Omaha, Nebraska.

<span class="mw-page-title-main">Jeeri R. Reddy</span>

Jeeri Reddy an American biologist who became an entrepreneur, developing new generation preventive and therapeutic vaccines. He has been an active leader in the field of the biopharmaceutical industry, commercializing diagnostics and vaccines through JN-International Medical Corporation. He is the scientific director and president of the corporation that created the world's first serological rapid tests for Tuberculosis to facilitate acid-fast bacilli microscopy for the identification of smear-positive and negative cases. Prevention of mother-to-child transmission of HIV was achieved in South East Asia by the use of rapid tests developed by Reddy in 1999. Reddy through his Corporation donated $173,050 worth of Rapid Diagnostic Tests (RDTs) for malaria in Zambia and actively participated in the prevention of child deaths due to Malaria infections. Reddy was personally invited by the president, George W. Bush, and First Lady Laura Bush to the White House for Malaria Awareness Day sponsored by US President Malaria Initiative (PMI) on Wednesday, April 25, 2007.

<span class="mw-page-title-main">Health in Niger</span>

Niger is a landlocked country located in West Africa and has Libya, Chad, Nigeria, Benin, Mali, Burkina Faso, and Algeria as its neighboring countries. Niger was French territory that got its independence in 1960 and its official language is French. Niger has an area of 1.267 million square kilometres, nevertheless, 80% of its land area spreads through the Sahara Desert.

<span class="mw-page-title-main">Health in Ghana</span>

In precolonial Ghana, infectious diseases were the main cause of morbidity and mortality. The modern history of health in Ghana was heavily influenced by international actors such as Christian missionaries, European colonists, the World Bank, and the International Monetary Fund. In addition, the democratic shift in Ghana spurred healthcare reforms in an attempt to address the presence of infectious and noncommunicable diseases eventually resulting in the formation of the National Health insurance Scheme in place today.

<span class="mw-page-title-main">Health in Cambodia</span>

The quality of health in Cambodia is rising along with its growing economy. The public health care system has a high priority from the Cambodian government and with international help and assistance, Cambodia has seen some major and continuous improvements in the health profile of its population since the 1980s, with a steadily rising life expectancy.

A vaccine-preventable disease is an infectious disease for which an effective preventive vaccine exists. If a person acquires a vaccine-preventable disease and dies from it, the death is considered a vaccine-preventable death.

<span class="mw-page-title-main">Health in Malawi</span>

Malawi ranks 170th out of 174 in the World Health Organization lifespan tables; 88% of the population live on less than £2.40 per day; and 50% are below the poverty line.

Patents for Humanity is an awards program run by the United States Patent and Trademark Office.

References

  1. ↑ "PATH 2020 Annual Report" (PDF). path.org. 2020. Archived (PDF) from the original on July 14, 2021. Retrieved July 16, 2021.
  2. ↑ Seattle Post-Intelligencer (May 21, 2007). "PATH, influential global health office, marks 30 years". Archived from the original on June 27, 2021. Retrieved February 13, 2013.
  3. 1 2 "Annual Report" (PDF). Retrieved 12 July 2024.
  4. ↑ "Vaccine Vial Monitors: "The Little Big Thing:" Taking Social Innovation to Scale". Stanford Graduate School of Business. Retrieved 2023-09-18.
  5. ↑ "WHO, UNICEF urge use of vaccine vial monitors". Infectious Disease News. June 2007. Retrieved 15 February 2013.
  6. ↑ "Health innovations in poorer countries". CNN. 16 July 2007. Archived from the original on 14 October 2012. Retrieved 15 February 2013.
  7. ↑ Timmerman, Luke (13 August 2008). "Seattle nonprofit PATH set to launch 'Ultra Rice' to fight global malnutrition". Xconomy. Archived from the original on 8 December 2012. Retrieved 15 February 2013.
  8. ↑ Heim, Kristi (24 July 2010). "Ultra Rice: Whatcom County invention holds hope for health". The Seattle Times. Archived from the original on 21 October 2012. Retrieved 15 February 2013.
  9. ↑ "Ultra Rice: A boost for malnourished children". World Vision website. Retrieved 15 February 2013.
  10. ↑ Staff, Post. "'Ultra Rice' slips nutrients in via one special grain for every 100 ordinary grains of rice". phnompenhpost.com. Retrieved 2023-09-18.
  11. ↑ "Urbano vai produzir ' Ultra Rice'". Abras. 23 February 2012. Retrieved 15 February 2013.
  12. ↑ "China's SFDA approves QIAGEN careHPV Test and instrument platform". News Medical. 29 November 2012. Retrieved 15 February 2013.
  13. ↑ "The Future of Birth Control". TIME. 6 January 2011. Archived from the original on 12 August 2014. Retrieved 15 February 2013.
  14. ↑ Nakkazi, Esther (24 July 2011). "Coming soon: An improved, noiseless female condom". The East African. Retrieved 15 February 2013.
  15. ↑ "Woman's Condom: Expanding Options for Dual Protection". Women Deliver website. Archived from the original on 20 November 2012. Retrieved 15 February 2013.
  16. ↑ "Taking on third world water". The Seattle Times. 9 December 2006. Archived from the original on 11 February 2014. Retrieved 15 February 2013.
  17. 1 2 Coghlan, Andy (14 June 2011). "Cheap vaccine eradicates new cases of meningitis A" . New Scientist. Retrieved 15 February 2013.
  18. ↑ "Africa: 100 Millionth Person Receives Lifesaving Meningitis Vaccine". All Africa. 3 December 2012. Retrieved 15 February 2013.
  19. ↑ Richard, Besser (8 March 2011). "Dr. Besser's Notebook: New Meningitis Shot Protects Hearing in Africa's Children". ABC News. Retrieved 15 February 2013.
  20. ↑ Miller, Talea (6 December 2010). "New Meningitis Vaccine Could be Model for Future Drugs". PBS NewsHour . Retrieved 15 February 2013.
  21. ↑ Knox, Richard (6 December 2010). "Africa's Meningitis Belt Gets First Vaccine Designed For Poor Nations". NPR. Archived from the original on 22 April 2014. Retrieved 15 February 2013.
  22. ↑ McNeil, Donald (19 November 2012). "Africa: A Change in Guidelines Could Extend a Vaccine's Reach in 'Meningitis Belt'". The New York Times. Archived from the original on 12 December 2012. Retrieved 15 February 2013.
  23. ↑ Parry, Jane (June 2007). "New vaccines to boost child care in developing countries". Bulletin of the World Health Organization. 85 (6): 426–427. doi:10.2471/BLT.07.020607 (inactive 5 December 2024). PMC   2636349 . PMID   17639237.{{cite journal}}: CS1 maint: DOI inactive as of December 2024 (link)
  24. ↑ Kelland, Kate (20 January 2011). "Studies show swift impact of rotavirus vaccines". Reuters. Archived from the original on 18 January 2016. Retrieved 15 February 2013.
  25. ↑ Fox, Maggie (2010-01-27). "Diarrhea vaccines could save 2 million lives: report". Reuters. Archived from the original on 2016-01-18. Retrieved 15 February 2013.
  26. ↑ Mason, Margie (26 July 2006). "India Launches Encephalitis Vaccination". The Washington Post. Retrieved 15 February 2013.
  27. ↑ "Immunisation drive against Japanese encephalitis". The Hindu . 26 July 2006. Archived from the original on 11 April 2013. Retrieved 15 February 2013.
  28. ↑ Brown, David (9 November 2012). "Tests find malaria vaccine useful". The Washington Post. Archived from the original on 22 April 2014. Retrieved 15 February 2013.
  29. ↑ Kelland, Kate (7 October 2013). "GSK aims to market world's first malaria vaccine". Reuters. Archived from the original on 18 January 2016. Retrieved 9 December 2013.
  30. 1 2 Bauman, Valerie (21 November 2012). "PATH leader: Fight against malaria making progress". Puget Sound Business Journal. Archived from the original on 12 July 2024. Retrieved 15 February 2013.
  31. ↑ "New Malaria Diagnosis and Treatment Project Awarded: MalariaCare". PMI Website. Archived from the original on 14 February 2013. Retrieved 15 February 2013.
  32. ↑ PATH. "From ancient China to a modern lab". PATH. Archived from the original on 9 February 2014. Retrieved 8 February 2014.
  33. ↑ Miller, Talea (31 October 2011). "Bio-Tech Breakthrough Could End Malaria Drug Shortages". PBS News Hour. Archived from the original on 18 February 2013. Retrieved 15 February 2013.
  34. ↑ Palmer, Eric (19 August 2014). "Sanofi shipping new malaria treatment manufactured from 'semisynthetic artemisinin'". fiercepharmamanufacturing.com. Archived from the original on 26 August 2014. Retrieved 14 September 2014.
  35. ↑ Mwololo, Millicent (30 November 2011). "Kenya: The Power to Protect and to Plan". All Africa. Archived from the original on 3 January 2012. Retrieved 15 February 2013.
  36. ↑ "KENYA: HIV prevention for married adolescents". IRIN/Plus News. 15 October 2010. Archived from the original on 12 July 2024. Retrieved 15 February 2013.
  37. ↑ "APHIAplus–Western Kenya". USAID Kenya website. Archived from the original on 20 February 2013. Retrieved 15 February 2013.
  38. ↑ "PATH secures major HIV/AIDS grants". The Seattle Times. 23 April 2009. Archived from the original on 24 April 2014. Retrieved 15 February 2013.
  39. ↑ Davidow, Julie (23 May 2005). "Street theater aims to get folks talking about health issues". Seattle Post-Intelligencer. Retrieved 15 February 2013.
  40. ↑ Vrinda, Malik (26 April 2012). "The snowball effect". The Hindu. Archived from the original on 30 June 2012. Retrieved 15 February 2013.
  41. ↑ "SA maternal and child death unacceptably high". MSN South Africa News. 9 September 2012. Archived from the original on 11 April 2013. Retrieved 15 February 2013.
  42. ↑ "Top 50 recipients of foundation grants in the state of Washington, circa 2010" (PDF). The Foundation Center. Archived from the original (PDF) on 10 February 2013. Retrieved 15 February 2013.
  43. ↑ The, Hindu (August 25, 2012). "Hindu report on HPV trials". The Hindu. Archived from the original on 13 November 2012. Retrieved 24 February 2013.
  44. ↑ "Is Bill Gates Being Sued by India Over Vaccination Deaths?". Snopes.com. 10 April 2020. Archived from the original on 2024-07-12. Retrieved 2021-03-21.
  45. ↑ "The Hindu Editorial". The Hindu. May 15, 2011. Archived from the original on 19 April 2012. Retrieved 24 February 2013.
  46. ↑ The Tech Museum Awards. "Annual Tech Museum Awards Grant $250,000 to Five Global Innovators". Archived from the original on March 11, 2010. Retrieved September 26, 2008.
  47. ↑ "PATH — Forbes.com". forbes.com. November 24, 2009. Archived from the original on November 29, 2009. Retrieved 24 May 2011.
  48. ↑ Fast Company. "45 Social Entrepreneurs Who Are Changing the World". Archived from the original on September 16, 2008. Retrieved September 26, 2008.
  49. ↑ Conrad N. Hilton Foundation. "Humanitarian Prize Recipients". Archived from the original on September 14, 2005. Retrieved November 13, 2009.
  50. ↑ "The Top 100 NGOs 2012". The Global Journal. 2012. Archived from the original on 26 March 2013. Retrieved 15 February 2013.
  51. ↑ "Charity Navigator — Rating for PATH". Charity Navigator. Archived from the original on 2020-09-26. Retrieved 2019-12-21.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.